Global Secondary Progressive Multiple Sclerosis Drug Market Growth 2022-2028

1.1 Market Introduction

1.2 Years Considered

1.3 Research Objectives

1.4 Market Research Methodology

1.5 Research Process and Data Source

1.6 Economic Indicators

1.7 Currency Considered

2 Executive Summary

2.1 World Market Overview

2.1.1 Global Secondary Progressive Multiple Sclerosis Drug Annual Sales 2017-2028

2.1.2 World Current & Future Analysis for Secondary Progressive Multiple Sclerosis Drug by Geographic Region, 2017, 2022 & 2028

2.1.3 World Current & Future Analysis for Secondary Progressive Multiple Sclerosis Drug by Country/Region, 2017, 2022 & 2028

2.2 Secondary Progressive Multiple Sclerosis Drug Segment by Type

2.2.1 Inebilizumab

2.2.2 GLX-1112

2.2.3 DC-TAB

2.2.4 Etomoxir

2.2.5 IB-MS

2.2.6 Others

2.3 Secondary Progressive Multiple Sclerosis Drug Sales by Type

2.3.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2017-2022)

2.3.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue and Market Share by Type (2017-2022)

2.3.3 Global Secondary Progressive Multiple Sclerosis Drug Sale Price by Type (2017-2022)

2.4 Secondary Progressive Multiple Sclerosis Drug Segment by Application

2.4.1 Hospital

2.4.2 Clinic

2.4.3 Others

2.5 Secondary Progressive Multiple Sclerosis Drug Sales by Application

2.5.1 Global Secondary Progressive Multiple Sclerosis Drug Sale Market Share by Application (2017-2022)

2.5.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue and Market Share by Application (2017-2022)

2.5.3 Global Secondary Progressive Multiple Sclerosis Drug Sale Price by Application (2017-2022)

3 Global Secondary Progressive Multiple Sclerosis Drug by Company

3.1 Global Secondary Progressive Multiple Sclerosis Drug Breakdown Data by Company

3.1.1 Global Secondary Progressive Multiple Sclerosis Drug Annual Sales by Company (2020-2022)

3.1.2 Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Company (2020-2022)

3.2 Global Secondary Progressive Multiple Sclerosis Drug Annual Revenue by Company (2020-2022)

3.2.1 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Company (2020-2022)

3.2.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Company (2020-2022)

3.3 Global Secondary Progressive Multiple Sclerosis Drug Sale Price by Company

3.4 Key Manufacturers Secondary Progressive Multiple Sclerosis Drug Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Secondary Progressive Multiple Sclerosis Drug Product Location Distribution

3.4.2 Players Secondary Progressive Multiple Sclerosis Drug Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 World Historic Review for Secondary Progressive Multiple Sclerosis Drug by Geographic Region

4.1 World Historic Secondary Progressive Multiple Sclerosis Drug Market Size by Geographic Region (2017-2022)

4.1.1 Global Secondary Progressive Multiple Sclerosis Drug Annual Sales by Geographic Region (2017-2022)

4.1.2 Global Secondary Progressive Multiple Sclerosis Drug Annual Revenue by Geographic Region

4.2 World Historic Secondary Progressive Multiple Sclerosis Drug Market Size by Country/Region (2017-2022)

4.2.1 Global Secondary Progressive Multiple Sclerosis Drug Annual Sales by Country/Region (2017-2022)

4.2.2 Global Secondary Progressive Multiple Sclerosis Drug Annual Revenue by Country/Region

4.3 Americas Secondary Progressive Multiple Sclerosis Drug Sales Growth

4.4 APAC Secondary Progressive Multiple Sclerosis Drug Sales Growth

4.5 Europe Secondary Progressive Multiple Sclerosis Drug Sales Growth

4.6 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales Growth

5 Americas

5.1 Americas Secondary Progressive Multiple Sclerosis Drug Sales by Country

5.1.1 Americas Secondary Progressive Multiple Sclerosis Drug Sales by Country (2017-2022)

5.1.2 Americas Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2017-2022)

5.2 Americas Secondary Progressive Multiple Sclerosis Drug Sales by Type

5.3 Americas Secondary Progressive Multiple Sclerosis Drug Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Secondary Progressive Multiple Sclerosis Drug Sales by Region

6.1.1 APAC Secondary Progressive Multiple Sclerosis Drug Sales by Region (2017-2022)

6.1.2 APAC Secondary Progressive Multiple Sclerosis Drug Revenue by Region (2017-2022)

6.2 APAC Secondary Progressive Multiple Sclerosis Drug Sales by Type

6.3 APAC Secondary Progressive Multiple Sclerosis Drug Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 Europe

7.1 Europe Secondary Progressive Multiple Sclerosis Drug by Country

7.1.1 Europe Secondary Progressive Multiple Sclerosis Drug Sales by Country (2017-2022)

7.1.2 Europe Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2017-2022)

7.2 Europe Secondary Progressive Multiple Sclerosis Drug Sales by Type

7.3 Europe Secondary Progressive Multiple Sclerosis Drug Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 Middle East & Africa

8.1 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug by Country

8.1.1 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales by Country (2017-2022)

8.1.2 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2017-2022)

8.2 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales by Type

8.3 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 Market Drivers, Challenges and Trends

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 Manufacturing Cost Structure Analysis

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Secondary Progressive Multiple Sclerosis Drug

10.3 Manufacturing Process Analysis of Secondary Progressive Multiple Sclerosis Drug

10.4 Industry Chain Structure of Secondary Progressive Multiple Sclerosis Drug

11 Marketing, Distributors and Customer

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Secondary Progressive Multiple Sclerosis Drug Distributors

11.3 Secondary Progressive Multiple Sclerosis Drug Customer

12 World Forecast Review for Secondary Progressive Multiple Sclerosis Drug by Geographic Region

12.1 Global Secondary Progressive Multiple Sclerosis Drug Market Size Forecast by Region

12.1.1 Global Secondary Progressive Multiple Sclerosis Drug Forecast by Region (2023-2028)

12.1.2 Global Secondary Progressive Multiple Sclerosis Drug Annual Revenue Forecast by Region (2023-2028)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Secondary Progressive Multiple Sclerosis Drug Forecast by Type

12.7 Global Secondary Progressive Multiple Sclerosis Drug Forecast by Application

13 Key Players Analysis

13.1 AB Science SA

13.1.1 AB Science SA Company Information

13.1.2 AB Science SA Secondary Progressive Multiple Sclerosis Drug Product Offered

13.1.3 AB Science SA Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.1.4 AB Science SA Main Business Overview

13.1.5 AB Science SA Latest Developments

13.2 Actelion Ltd

13.2.1 Actelion Ltd Company Information

13.2.2 Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Product Offered

13.2.3 Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.2.4 Actelion Ltd Main Business Overview

13.2.5 Actelion Ltd Latest Developments

13.3 Biogen, Inc.

13.3.1 Biogen, Inc. Company Information

13.3.2 Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Product Offered

13.3.3 Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.3.4 Biogen, Inc. Main Business Overview

13.3.5 Biogen, Inc. Latest Developments

13.4 F. Hoffmann-La Roche Ltd.

13.4.1 F. Hoffmann-La Roche Ltd. Company Information

13.4.2 F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Product Offered

13.4.3 F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.4.4 F. Hoffmann-La Roche Ltd. Main Business Overview

13.4.5 F. Hoffmann-La Roche Ltd. Latest Developments

13.5 Genzyme Corporation

13.5.1 Genzyme Corporation Company Information

13.5.2 Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Product Offered

13.5.3 Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.5.4 Genzyme Corporation Main Business Overview

13.5.5 Genzyme Corporation Latest Developments

13.6 Glialogix, Inc.

13.6.1 Glialogix, Inc. Company Information

13.6.2 Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Product Offered

13.6.3 Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.6.4 Glialogix, Inc. Main Business Overview

13.6.5 Glialogix, Inc. Latest Developments

13.7 Immune Response BioPharma, Inc.

13.7.1 Immune Response BioPharma, Inc. Company Information

13.7.2 Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Product Offered

13.7.3 Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.7.4 Immune Response BioPharma, Inc. Main Business Overview

13.7.5 Immune Response BioPharma, Inc. Latest Developments

13.8 Innate Immunotherapeutics Ltd

13.8.1 Innate Immunotherapeutics Ltd Company Information

13.8.2 Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Product Offered

13.8.3 Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.8.4 Innate Immunotherapeutics Ltd Main Business Overview

13.8.5 Innate Immunotherapeutics Ltd Latest Developments

13.9 Kyorin Pharmaceutical Co., Ltd.

13.9.1 Kyorin Pharmaceutical Co., Ltd. Company Information

13.9.2 Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Product Offered

13.9.3 Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.9.4 Kyorin Pharmaceutical Co., Ltd. Main Business Overview

13.9.5 Kyorin Pharmaceutical Co., Ltd. Latest Developments

13.10 Mallinckrodt Plc

13.10.1 Mallinckrodt Plc Company Information

13.10.2 Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Product Offered

13.10.3 Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.10.4 Mallinckrodt Plc Main Business Overview

13.10.5 Mallinckrodt Plc Latest Developments

13.11 MedDay SA

13.11.1 MedDay SA Company Information

13.11.2 MedDay SA Secondary Progressive Multiple Sclerosis Drug Product Offered

13.11.3 MedDay SA Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.11.4 MedDay SA Main Business Overview

13.11.5 MedDay SA Latest Developments

13.12 MedImmune, LLC

13.12.1 MedImmune, LLC Company Information

13.12.2 MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Product Offered

13.12.3 MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.12.4 MedImmune, LLC Main Business Overview

13.12.5 MedImmune, LLC Latest Developments

13.13 Merck KGaA

13.13.1 Merck KGaA Company Information

13.13.2 Merck KGaA Secondary Progressive Multiple Sclerosis Drug Product Offered

13.13.3 Merck KGaA Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.13.4 Merck KGaA Main Business Overview

13.13.5 Merck KGaA Latest Developments

13.14 Meta-IQ ApS

13.14.1 Meta-IQ ApS Company Information

13.14.2 Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Product Offered

13.14.3 Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.14.4 Meta-IQ ApS Main Business Overview

13.14.5 Meta-IQ ApS Latest Developments

13.15 Novartis AG

13.15.1 Novartis AG Company Information

13.15.2 Novartis AG Secondary Progressive Multiple Sclerosis Drug Product Offered

13.15.3 Novartis AG Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.15.4 Novartis AG Main Business Overview

13.15.5 Novartis AG Latest Developments

13.16 Opexa Therapeutics, Inc.

13.16.1 Opexa Therapeutics, Inc. Company Information

13.16.2 Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Product Offered

13.16.3 Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.16.4 Opexa Therapeutics, Inc. Main Business Overview

13.16.5 Opexa Therapeutics, Inc. Latest Developments

13.17 Xenetic Biosciences (UK) Limited

13.17.1 Xenetic Biosciences (UK) Limited Company Information

13.17.2 Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Product Offered

13.17.3 Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.17.4 Xenetic Biosciences (UK) Limited Main Business Overview

13.17.5 Xenetic Biosciences (UK) Limited Latest Developments

14 Research Findings and Conclusion

Table 1. Secondary Progressive Multiple Sclerosis Drug Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)

Table 2. Secondary Progressive Multiple Sclerosis Drug Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)

Table 3. Major Players of Inebilizumab

Table 4. Major Players of GLX-1112

Table 5. Major Players of DC-TAB

Table 6. Major Players of Etomoxir

Table 7. Major Players of IB-MS

Table 8. Major Players of Others

Table 9. Global Secondary Progressive Multiple Sclerosis Drug Sales by Type (2017-2022) & (K Pcs)

Table 10. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2017-2022)

Table 11. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Type (2017-2022) & ($ million)

Table 12. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Type (2017-2022)

Table 13. Global Secondary Progressive Multiple Sclerosis Drug Sale Price by Type (2017-2022) & (USD/Pcs)

Table 14. Global Secondary Progressive Multiple Sclerosis Drug Sales by Application (2017-2022) & (K Pcs)

Table 15. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2017-2022)

Table 16. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Application (2017-2022)

Table 17. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Application (2017-2022)

Table 18. Global Secondary Progressive Multiple Sclerosis Drug Sale Price by Application (2017-2022) & (USD/Pcs)

Table 19. Global Secondary Progressive Multiple Sclerosis Drug Sales by Company (2020-2022) & (K Pcs)

Table 20. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Company (2020-2022)

Table 21. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Company (2020-2022) ($ Millions)

Table 22. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Company (2020-2022)

Table 23. Global Secondary Progressive Multiple Sclerosis Drug Sale Price by Company (2020-2022) & (USD/Pcs)

Table 24. Key Manufacturers Secondary Progressive Multiple Sclerosis Drug Producing Area Distribution and Sales Area

Table 25. Players Secondary Progressive Multiple Sclerosis Drug Products Offered

Table 26. Secondary Progressive Multiple Sclerosis Drug Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

Table 27. New Products and Potential Entrants

Table 28. Mergers & Acquisitions, Expansion

Table 29. Global Secondary Progressive Multiple Sclerosis Drug Sales by Geographic Region (2017-2022) & (K Pcs)

Table 30. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share Geographic Region (2017-2022)

Table 31. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Geographic Region (2017-2022) & ($ millions)

Table 32. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Geographic Region (2017-2022)

Table 33. Global Secondary Progressive Multiple Sclerosis Drug Sales by Country/Region (2017-2022) & (K Pcs)

Table 34. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country/Region (2017-2022)

Table 35. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Country/Region (2017-2022) & ($ millions)

Table 36. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Country/Region (2017-2022)

Table 37. Americas Secondary Progressive Multiple Sclerosis Drug Sales by Country (2017-2022) & (K Pcs)

Table 38. Americas Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country (2017-2022)

Table 39. Americas Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2017-2022) & ($ Millions)

Table 40. Americas Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Country (2017-2022)

Table 41. Americas Secondary Progressive Multiple Sclerosis Drug Sales by Type (2017-2022) & (K Pcs)

Table 42. Americas Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2017-2022)

Table 43. Americas Secondary Progressive Multiple Sclerosis Drug Sales by Application (2017-2022) & (K Pcs)

Table 44. Americas Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2017-2022)

Table 45. APAC Secondary Progressive Multiple Sclerosis Drug Sales by Region (2017-2022) & (K Pcs)

Table 46. APAC Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Region (2017-2022)

Table 47. APAC Secondary Progressive Multiple Sclerosis Drug Revenue by Region (2017-2022) & ($ Millions)

Table 48. APAC Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Region (2017-2022)

Table 49. APAC Secondary Progressive Multiple Sclerosis Drug Sales by Type (2017-2022) & (K Pcs)

Table 50. APAC Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2017-2022)

Table 51. APAC Secondary Progressive Multiple Sclerosis Drug Sales by Application (2017-2022) & (K Pcs)

Table 52. APAC Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2017-2022)

Table 53. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Country (2017-2022) & (K Pcs)

Table 54. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country (2017-2022)

Table 55. Europe Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2017-2022) & ($ Millions)

Table 56. Europe Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Country (2017-2022)

Table 57. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Type (2017-2022) & (K Pcs)

Table 58. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2017-2022)

Table 59. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Application (2017-2022) & (K Pcs)

Table 60. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2017-2022)

Table 61. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales by Country (2017-2022) & (K Pcs)

Table 62. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country (2017-2022)

Table 63. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2017-2022) & ($ Millions)

Table 64. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Country (2017-2022)

Table 65. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales by Type (2017-2022) & (K Pcs)

Table 66. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2017-2022)

Table 67. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales by Application (2017-2022) & (K Pcs)

Table 68. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2017-2022)

Table 69. Key Market Drivers & Growth Opportunities of Secondary Progressive Multiple Sclerosis Drug

Table 70. Key Market Challenges & Risks of Secondary Progressive Multiple Sclerosis Drug

Table 71. Key Industry Trends of Secondary Progressive Multiple Sclerosis Drug

Table 72. Secondary Progressive Multiple Sclerosis Drug Raw Material

Table 73. Key Suppliers of Raw Materials

Table 74. Secondary Progressive Multiple Sclerosis Drug Distributors List

Table 75. Secondary Progressive Multiple Sclerosis Drug Customer List

Table 76. Global Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Region (2023-2028) & (K Pcs)

Table 77. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Forecast by Region

Table 78. Global Secondary Progressive Multiple Sclerosis Drug Revenue Forecast by Region (2023-2028) & ($ millions)

Table 79. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share Forecast by Region (2023-2028)

Table 80. Americas Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Country (2023-2028) & (K Pcs)

Table 81. Americas Secondary Progressive Multiple Sclerosis Drug Revenue Forecast by Country (2023-2028) & ($ millions)

Table 82. APAC Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Region (2023-2028) & (K Pcs)

Table 83. APAC Secondary Progressive Multiple Sclerosis Drug Revenue Forecast by Region (2023-2028) & ($ millions)

Table 84. Europe Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Country (2023-2028) & (K Pcs)

Table 85. Europe Secondary Progressive Multiple Sclerosis Drug Revenue Forecast by Country (2023-2028) & ($ millions)

Table 86. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Country (2023-2028) & (K Pcs)

Table 87. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Revenue Forecast by Country (2023-2028) & ($ millions)

Table 88. Global Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Type (2023-2028) & (K Pcs)

Table 89. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share Forecast by Type (2023-2028)

Table 90. Global Secondary Progressive Multiple Sclerosis Drug Revenue Forecast by Type (2023-2028) & ($ Millions)

Table 91. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share Forecast by Type (2023-2028)

Table 92. Global Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Application (2023-2028) & (K Pcs)

Table 93. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share Forecast by Application (2023-2028)

Table 94. Global Secondary Progressive Multiple Sclerosis Drug Revenue Forecast by Application (2023-2028) & ($ Millions)

Table 95. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share Forecast by Application (2023-2028)

Table 96. AB Science SA Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 97. AB Science SA Secondary Progressive Multiple Sclerosis Drug Product Offered

Table 98. AB Science SA Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 99. AB Science SA Main Business

Table 100. AB Science SA Latest Developments

Table 101. Actelion Ltd Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 102. Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Product Offered

Table 103. Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 104. Actelion Ltd Main Business

Table 105. Actelion Ltd Latest Developments

Table 106. Biogen, Inc. Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 107. Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Product Offered

Table 108. Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 109. Biogen, Inc. Main Business

Table 110. Biogen, Inc. Latest Developments

Table 111. F. Hoffmann-La Roche Ltd. Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 112. F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Product Offered

Table 113. F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 114. F. Hoffmann-La Roche Ltd. Main Business

Table 115. F. Hoffmann-La Roche Ltd. Latest Developments

Table 116. Genzyme Corporation Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 117. Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Product Offered

Table 118. Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 119. Genzyme Corporation Main Business

Table 120. Genzyme Corporation Latest Developments

Table 121. Glialogix, Inc. Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 122. Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Product Offered

Table 123. Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 124. Glialogix, Inc. Main Business

Table 125. Glialogix, Inc. Latest Developments

Table 126. Immune Response BioPharma, Inc. Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 127. Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Product Offered

Table 128. Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 129. Immune Response BioPharma, Inc. Main Business

Table 130. Immune Response BioPharma, Inc. Latest Developments

Table 131. Innate Immunotherapeutics Ltd Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 132. Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Product Offered

Table 133. Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 134. Innate Immunotherapeutics Ltd Main Business

Table 135. Innate Immunotherapeutics Ltd Latest Developments

Table 136. Kyorin Pharmaceutical Co., Ltd. Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 137. Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Product Offered

Table 138. Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 139. Kyorin Pharmaceutical Co., Ltd. Main Business

Table 140. Kyorin Pharmaceutical Co., Ltd. Latest Developments

Table 141. Mallinckrodt Plc Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 142. Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Product Offered

Table 143. Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 144. Mallinckrodt Plc Main Business

Table 145. Mallinckrodt Plc Latest Developments

Table 146. MedDay SA Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 147. MedDay SA Secondary Progressive Multiple Sclerosis Drug Product Offered

Table 148. MedDay SA Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 149. MedDay SA Main Business

Table 150. MedDay SA Latest Developments

Table 151. MedImmune, LLC Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 152. MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Product Offered

Table 153. MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 154. MedImmune, LLC Main Business

Table 155. MedImmune, LLC Latest Developments

Table 156. Merck KGaA Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 157. Merck KGaA Secondary Progressive Multiple Sclerosis Drug Product Offered

Table 158. Merck KGaA Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 159. Merck KGaA Main Business

Table 160. Merck KGaA Latest Developments

Table 161. Meta-IQ ApS Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 162. Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Product Offered

Table 163. Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 164. Meta-IQ ApS Main Business

Table 165. Meta-IQ ApS Latest Developments

Table 166. Novartis AG Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 167. Novartis AG Secondary Progressive Multiple Sclerosis Drug Product Offered

Table 168. Novartis AG Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 169. Novartis AG Main Business

Table 170. Novartis AG Latest Developments

Table 171. Opexa Therapeutics, Inc. Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 172. Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Product Offered

Table 173. Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 174. Opexa Therapeutics, Inc. Main Business

Table 175. Opexa Therapeutics, Inc. Latest Developments

Table 176. Xenetic Biosciences (UK) Limited Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 177. Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Product Offered

Table 178. Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 179. Xenetic Biosciences (UK) Limited Main Business

Table 180. Xenetic Biosciences (UK) Limited Latest Developments

List of Figures

Figure 1. Picture of Secondary Progressive Multiple Sclerosis Drug

Figure 2. Secondary Progressive Multiple Sclerosis Drug Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate 2017-2028 (K Pcs)

Figure 7. Global Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate 2017-2028 ($ Millions)

Figure 8. Secondary Progressive Multiple Sclerosis Drug Sales by Region (2021 & 2028) & ($ millions)

Figure 9. Product Picture of Inebilizumab

Figure 10. Product Picture of GLX-1112

Figure 11. Product Picture of DC-TAB

Figure 12. Product Picture of Etomoxir

Figure 13. Product Picture of IB-MS

Figure 14. Product Picture of Others

Figure 15. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type in 2021

Figure 16. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Type (2017-2022)

Figure 17. Secondary Progressive Multiple Sclerosis Drug Consumed in Hospital

Figure 18. Global Secondary Progressive Multiple Sclerosis Drug Market: Hospital (2017-2022) & (K Pcs)

Figure 19. Secondary Progressive Multiple Sclerosis Drug Consumed in Clinic

Figure 20. Global Secondary Progressive Multiple Sclerosis Drug Market: Clinic (2017-2022) & (K Pcs)

Figure 21. Secondary Progressive Multiple Sclerosis Drug Consumed in Others

Figure 22. Global Secondary Progressive Multiple Sclerosis Drug Market: Others (2017-2022) & (K Pcs)

Figure 23. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2017-2022)

Figure 24. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Application in 2021

Figure 25. Secondary Progressive Multiple Sclerosis Drug Revenue Market by Company in 2021 ($ Million)

Figure 26. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Company in 2021

Figure 27. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Geographic Region (2017-2022)

Figure 28. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Geographic Region in 2021

Figure 29. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Region (2017-2022)

Figure 30. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Country/Region in 2021

Figure 31. Americas Secondary Progressive Multiple Sclerosis Drug Sales 2017-2022 (K Pcs)

Figure 32. Americas Secondary Progressive Multiple Sclerosis Drug Revenue 2017-2022 ($ Millions)

Figure 33. APAC Secondary Progressive Multiple Sclerosis Drug Sales 2017-2022 (K Pcs)

Figure 34. APAC Secondary Progressive Multiple Sclerosis Drug Revenue 2017-2022 ($ Millions)

Figure 35. Europe Secondary Progressive Multiple Sclerosis Drug Sales 2017-2022 (K Pcs)

Figure 36. Europe Secondary Progressive Multiple Sclerosis Drug Revenue 2017-2022 ($ Millions)

Figure 37. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales 2017-2022 (K Pcs)

Figure 38. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Revenue 2017-2022 ($ Millions)

Figure 39. Americas Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country in 2021

Figure 40. Americas Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Country in 2021

Figure 41. United States Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 42. Canada Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 43. Mexico Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 44. Brazil Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 45. APAC Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Region in 2021

Figure 46. APAC Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Regions in 2021

Figure 47. China Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 48. Japan Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 49. South Korea Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 50. Southeast Asia Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 51. India Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 52. Australia Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 53. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country in 2021

Figure 54. Europe Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Country in 2021

Figure 55. Germany Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 56. France Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 57. UK Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 58. Italy Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 59. Russia Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 60. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country in 2021

Figure 61. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Country in 2021

Figure 62. Egypt Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 63. South Africa Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 64. Israel Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 65. Turkey Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 66. GCC Country Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 67. Manufacturing Cost Structure Analysis of Secondary Progressive Multiple Sclerosis Drug in 2021

Figure 68. Manufacturing Process Analysis of Secondary Progressive Multiple Sclerosis Drug

Figure 69. Industry Chain Structure of Secondary Progressive Multiple Sclerosis Drug

Figure 70. Channels of Distribution

Figure 71. Distributors Profiles